Phibro Animal Health (NASDAQ:PAHC) Upgraded at Zacks Research

Zacks Research upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a hold rating to a strong-buy rating in a research note published on Wednesday,Zacks.com reports. Zacks Research also issued estimates for Phibro Animal Health’s Q3 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.66 EPS, FY2026 earnings at $2.98 EPS, Q1 2027 earnings at $0.77 EPS, Q2 2027 earnings at $0.78 EPS, FY2027 earnings at $3.05 EPS, Q1 2028 earnings at $0.79 EPS and FY2028 earnings at $3.17 EPS.

Other analysts have also recently issued reports about the stock. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Phibro Animal Health Trading Up 1.0%

Shares of NASDAQ:PAHC opened at $49.47 on Wednesday. The stock’s 50-day simple moving average is $46.32 and its two-hundred day simple moving average is $42.18. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 21.99, a PEG ratio of 0.75 and a beta of 0.74. Phibro Animal Health has a 52-week low of $16.16 and a 52-week high of $56.30. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Analysts expect that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.0%. Phibro Animal Health’s payout ratio is 21.33%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20. Following the sale, the chief executive officer owned 1,480 shares in the company, valued at approximately $79,520.40. This trade represents a 82.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 288,640 shares of company stock valued at $13,821,518. Corporate insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently modified their holdings of PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after purchasing an additional 546 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after buying an additional 154,281 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after buying an additional 13,404 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Phibro Animal Health by 97.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock worth $621,000 after buying an additional 11,999 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Phibro Animal Health by 0.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 268,877 shares of the company’s stock worth $6,867,000 after buying an additional 906 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health News Summary

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research upgraded PAHC from “Hold” to “Strong Buy” (3/13), signaling a more bullish view from a widely followed research shop — a near-term catalyst for buying interest. Read More.
• Positive Sentiment: Zacks lifted multiple quarterly and full‑year EPS forecasts across FY2026–FY2028 (modest increases: FY2026 to ~$2.98, FY2027 to ~$3.05, FY2028 to ~$3.17), which supports higher forward earnings expectations and valuation support. Read More.
• Positive Sentiment: Zacks featured PAHC on a GARP (growth-at-a-reasonable-price) stock roundup, highlighting it as a candidate for investors seeking growth with value characteristics — this can attract longer‑term, fundamentals‑driven flows. Read More.
• Positive Sentiment: PAHC was named to Zacks Rank #1 (Strong Buy) value stocks list on March 12, a separate endorsement that can draw attention from value-oriented retail and institutional buyers. Read More.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.